A Phase 2 interventional study of JNJ-67953964 and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 53 sites in 6 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 29th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2018, is one of 17 in phase 2, and was the 31st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
Intra-Cellular Therapies, Inc. · Sites in United States, Bulgaria, France and 4 more countries
Ages 18–65
Intra-Cellular Therapies, Inc.
Ages 18–74
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 203 across the 52 interventional studies, 136 across the 7 observational. Of the 53 that completed or were terminated, 26 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
2 of the studies in Depressive Disorder, Major by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have a primary 5th edition (DSM-5) diagnosis of Major Depressive Disorder (MDD)
Exclusion Criteria:
Has one or more of the following diagnoses:
Participant has used:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive matching placebo for the entire duration of the lead-in period.
Drug: Placebo
Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2\*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
Drug: JNJ-67953964 · Drug: Placebo
Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
Drug: Placebo
JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
Matching placebo will be administered as 2 capsules orally once daily.
Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in MADRS Total Score at Treatment Week 6
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period
An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. TEAEs were AEs with onset during the treatment period that has worsened since baseline.
Time frame: Up to Week 6
Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population)
The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT)
The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population)
CGI-S provides an overall clinician-determined summary measure of severity of participant's illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population)
CGI-S provides an overall clinician-determined summary measure of severity of participants illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population)
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population)
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Number of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population)
SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.
Time frame: Treatment Week 6
Number of Participants With SATE Questionnaire at Treatment Week 6 (fITT Population)
SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.
Time frame: Treatment Week 6
Change From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population)
HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT)
HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population)
SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Change From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population)
SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.
Time frame: Treatment Baseline up to Week 6 of DB-treatment period
Maximum Observed Plasma Concentration (Cmax) of JNJ-67953964
Cmax was defined as maximum observed plasma concentration of JNJ-67953964.
Time frame: Week 1: Day 29, Week 3: Day 43, Week 6 (Day 64)
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC[0-24h]) of JNJ-67953964
AUC(0-24h) was defined as the area under the plasma concentration-time curve from time of administration to 24 hours.
Time frame: 0 to 24 hours Post dose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64
Area Under Plasma Concentration-Time Curve at Steady State (AUCss) of JNJ-67953964
AUCss was defined as the area under plasma concentration-time curve at Steady State (AUCss) of JNJ-67953964.
Time frame: Week 1: Day 29, Week 3: Day 43, Week 6: Day 64
Predose (Trough) Plasma Concentration (C0h) of JNJ-67953964
C0h was defined as predose plasma Concentration of JNJ-67953964.
Time frame: Predose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64
| Milestone | Lead in Period: Placebo | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|---|
| Started | 181 | 0 | 0 |
| Completed | 169 | 0 | 0 |
| Not completed | 12 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 |
| Milestone | Lead in Period: Placebo | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|---|
| Started | 0 | 84 | 85 |
| Placebo lead-in responders | 0 | 22 | 23 |
| Placebo lead-in non-responders | 0 | 62 | 62 |
| Completed db period and entered withdrawal | 0 | 81 | 80 |
| Completed | 0 | 81 | 79 |
| Not completed | 0 | 3 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 1 |
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period | -8.0 ± 0.92 | -10.1 ± 0.93 |
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in MADRS Total Score at Treatment Week 6 | -6.5 ± 0.78 | -9.6 ± 0.79 |
An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. TEAEs were AEs with onset during the treatment period that has worsened since baseline.
| Participants | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period | 30 | 40 |
The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population) | -3.7 ± 0.64 | -4.4 ± 0.64 |
The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT) | -3.7 ± 0.55 | -4.5 ± 0.55 |
CGI-S provides an overall clinician-determined summary measure of severity of participant's illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.
| Scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population) | -0.76 ± 0.858 | -0.92 ± 1.039 |
CGI-S provides an overall clinician-determined summary measure of severity of participants illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.
| Scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population) | -0.67 ± 0.880 | -0.87 ± 1.005 |
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.
| Scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population) | -8.49 ± 9.567 | -8.03 ± 9.957 |
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.
| Scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population) | -6.91 ± 9.996 | -8.16 ± 9.470 |
SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.
| Participants | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Overall Depression (Got worse) | 1 | 0 |
| Overall Depression (Not changed) | 12 | 9 |
| Overall Depression (Improved) | 27 | 21 |
| Depression Worsened (Slightly worse) | 1 | — |
| Depression Worsened (Much worse) | 0 | — |
| Depression Worsened (Very much worse) | 0 | — |
| Depression Improvement (Slightly improved) | 13 | 15 |
| Depression Improvement (Much improved) | 11 | 6 |
| Depression Improvement (Very Much Improved) | 3 | 0 |
SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.
| Participants | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Overall Depression (Got worse) | 1 | 0 |
| Overall Depression (Not changed) | 15 | 12 |
| Overall Depression (Improved) | 33 | 30 |
| Depression Worsened (Slightly worse) | 1 | — |
| Depression Worsened (Much worse) | 0 | — |
| Depression Worsened (Very much worse) | 0 | — |
| Depression Improvement (Slightly improved) | 18 | 20 |
| Depression Improvement (Much improved) | 12 | 9 |
| Depression Improvement (Very Much Improved) | 3 | 1 |
HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population) | -2.19 ± 2.837 | -2.73 ± 2.651 |
HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT) | -1.67 ± 2.842 | -2.68 ± 2.562 |
SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population) | -5.37 ± 6.549 | -5.85 ± 5.369 |
SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.
| scores on a scale | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|
| Change From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population) | -4.35 ± 6.193 | -5.47 ± 4.988 |
Cmax was defined as maximum observed plasma concentration of JNJ-67953964.
| nanograms per milliliter (ng/mL) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|
| Week 1 (Day 29) | 32.7 ± 10.9 |
| Week 3 (Day 43) | 33.5 ± 11.1 |
| Week 6 (Day 64) | 34.3 ± 11.1 |
AUC(0-24h) was defined as the area under the plasma concentration-time curve from time of administration to 24 hours.
| nanograms*hour per milliliter (ng*h/mL) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|
| Week 1 (Day 29) | 361 ± 156 |
| Week 3 (Day 43) | 377 ± 164 |
| Week 6 (Day 64) | 378 ± 163 |
AUCss was defined as the area under plasma concentration-time curve at Steady State (AUCss) of JNJ-67953964.
| ng*h/mL | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|
| Week 1 (Day 29) | 380 ± 151 |
| Week 3 (Day 43) | 380 ± 151 |
| Week 6 (Day 64) | 379 ± 153 |
C0h was defined as predose plasma Concentration of JNJ-67953964.
| nanograms per milliliter (ng/ml) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|
| Week 1 (Day 29) | 8.62 ± 4.27 |
| Week 3 (Day 43) | 9.40 ± 4.69 |
| Week 6 (Day 64) | 9.48 ± 4.83 |
Collected over Up to Week 11. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lead in Period: Placebo | 0/169 (0%) | 0/169 (0%) | 21/169 (12.4%) |
| Double-blind Treatment + Withdrawal Period: Placebo | 0/84 (0%) | 1/84 (1.2%) | 10/84 (11.9%) |
| Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 0/85 (0%) | 0/85 (0%) | 23/85 (27.1%) |
| Event | Lead in Period: Placebo | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|---|
| Cholecystitis AcuteHepatobiliary disorders | 0/169 | 1/84 | 0/85 |
| Event | Lead in Period: Placebo | Double-blind Treatment + Withdrawal Period: Placebo | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) |
|---|---|---|---|
| HeadacheNervous system disorders | 11/169 | 7/84 | 10/85 |
| DiarrhoeaGastrointestinal disorders | 6/169 | 2/84 | 7/85 |
| NasopharyngitisInfections and infestations | 6/169 | 3/84 | 6/85 |
| PruritusSkin and subcutaneous tissue disorders | 1/169 | 0/84 | 5/85 |
| Age, Continuous(years) | Lead in Period: Placebo |
|---|---|
| Mean | 42.5 ± 12.91 |
| Age, Customized(Participants) | Lead in Period: Placebo |
|---|---|
| Adults (18-64 years) | 181 |
| Sex: Female, Male(Participants) | Lead in Period: Placebo |
|---|---|
| Female | 131 |
| Male | 50 |
| Ethnicity (NIH/OMB)(Participants) | Lead in Period: Placebo |
|---|---|
| Hispanic or Latino | 25 |
| Not Hispanic or Latino | 156 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lead in Period: Placebo |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 8 |
| White | 167 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in May 2020, 21 months.
Results were first posted in Jun 2023, 3 years 1 month after primary completion. A results delay was requested in May 2021.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 21 months is above that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aticaprant
Janssen Research & Development, LLC →